Molecular BrainNeurosciencePeer-reviewed journal article
Serotonin Enhances Neurogenesis Biomarkers, Hippocampal Volumes, and Cognitive Functions in Alzheimer's Disease
Ali AzargoonjahromiiD, Alzheimer’s Disease Neuroimaging Initiative
Abstract
Research on serotonin reveals a lack of consensus regarding its role in brain volume, especially concerning biomarkers linked to neurogenesis and neuroplasticity, such as ciliary neurotrophic factor (CNTF), fibroblast growth factor 4 (FGF-4), bone morphogenetic protein 6 (BMP-6), and matrix metalloproteinase-1 (MMP-1) in Alzheimers disease (AD). This study aimed to investigate the influence of serotonin on brain structure and hippocampal volumes in relation to cognitive functions in AD, as well as its link with biomarkers like CNTF, FGF-4, BMP-6, and MMP-1. Data from the ADNI included 133 AD participants. Cognitive function was assessed using CDR-SB, serotonin levels were measured with the Biocrates AbsoluteIDQ p180 kit and UPLC-MS/MS, and neurotrophic factors and biomarkers were quantified using multiplex targeted proteomics. Voxel-Based Morphometry (VBM) analyzed gray matter volume changes via MRI. Statistical analyses employed Pearson correlation and Bootstrap methods, with p-values View larger version (19K): org.highwire.dtl.DTLVardef@c020eaorg.highwire.dtl.DTLVardef@1b104e2org.highwire.dtl.DTLVardef@b7bc5borg.highwire.dtl.DTLVardef@aeffdc_HPS_FORMAT_FIGEXP M_FIG C_FIG Serotonin plays a key role in cognitive function, with higher levels linked to increased brain and hippocampal volumes and better cognitive performance, as shown by lower CDR-SB scores (indicating less cognitive impairment). In addition, serotonin is positively associated with neurotrophic factors and biomarkers like ciliary neurotrophic factor (CNTF), fibroblast growth factor 4 (FGF-4), bone morphogenetic protein 6 (BMP-6), and matrix metalloproteinase-1 (MMP-1), which are involved in neurogenesis and neuroplasticity. These findings suggest that elevated serotonin levels contribute to brain health, cognitive function, and the promotion of neural growth and plasticity, particularly in Alzheimers disease (AD).
- Citations
- 28
- FWCI
- 8.19
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Perivascular spaces in Alzheimer's disease are associated with inflammatory, stress-related, and hypertension biomarkers
Francesca Sibilia, Nasim Sheikh‐Bahaei, … Jeiran Choupan·bioRxiv·Jun 2, 2023
- Clinical and biomarker changes in sporadic Alzheimer's disease
Junjie Zhuo, Yuanchao Zhang, … the Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·May 8, 2020
- CSF biomarkers are differentially related to structural and functional changes in dementia of the Alzheimer’s type
Charles Benjamin Malpas, Michael Martin Saling, … Terence John O'Brien·Journal of Alzheimer s DiseasePeer-reviewed·Feb 6, 2018
- Elevated Na+/K+ Ratio in Alzheimers Disease: A Potential Biomarker for Braak Stage
Yuma Mizuno, Shiyue Pan, … Yumei Feng·International Journal of Molecular SciencesPeer-reviewed·Jan 27, 2026
- Serum Metabolites Associate with Brain Amyloid Beta Deposition, Cognitive Dysfunction, and Alzheimers Disease Progression
Kwangsik T. Nho, Alexandra Kueider‐Paisley, … Andrew J. Saykin·bioRxiv·Nov 25, 2020
- Mapping Sleep's Oscillatory Events as a Biomarker of Alzheimer's Disease
Rachelle L. Pulver, Eugene Kronberg, … Brice V. McConnell·Alzheimer s & DementiaPeer-reviewed·Aug 23, 2023